Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20

Aishwarya Shivaraman; Nicole Guilz

Loading [Contrib]/a11y/accessibility-menu.js

Review paper

March 17, 2022 CDT

Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20

Aishwarya Shivaraman , Nicole Guilz ,

Immunotherapy Rheumatoid arthritis PTPN22 T cells B cells CRISPR/Cas9 PDCD1 PD-1 MS4A1 CD20

ccby-nc-sa-4.0

JHSS

Shivaraman, Aishwarya, and Nicole Guilz. 2022. “Immunotherapy Using CRISPR-Cas9 Systems to Treat Rheumatoid Arthritis with PTPN22 R620W Mutations and Target PD-1 and CD20.” Journal of High School Science, March.

View more stats